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INTRODUCTION
Frailty syndrome among older people is related to changes that occur through the human 
aging process, such as sarcopenia, neuroendocrine dysregulation and immune system dys-
function.1 Frail individuals are at increased risk of adverse events and injuries due to falls, 
which, together with various comorbidities, can cause higher rates of institutional care, hos-
pitalizations and mortality.1,2 
The aging process can promote physiological changes that cause older people to exhibit dis-
tinctive pharmacokinetics, such that they may become more sensitive both to the therapeutic 
effects and to the toxic effects of drug therapy.3 Furthermore, multimorbid conditions require 
the use of multiple drugs, which is characterized as polypharmacy. This, together with the phys-
iological changes of aging can increase the chances of adverse events among older people.3-6 
These include the increased levels of pathogenesis within frailty syndrome, as highlighted in the 
International Frailty Consensus.7
There are several concepts of polypharmacy, although most of them consider it to be 
the concomitant use of five or more drugs.8 This was the concept used in the present inves-
tigation. It is important to note that polypharmacy increases the risk of drug interactions 
(DI), as well as the use of potentially inappropriate medications (PIMs) among older peo-
ple.3 Polypharmacy, therefore, cannot be considered to be the only marker for assessing the 
quality of drug prescriptions,9 which requires consideration of DIs and use of PIMs for clin-
ical care among older people.
DIs consist of clinically significant changes to the effect of a given drug caused by admin-
istration of another drug. Such changes may lead to modification of the absorption capacity to 
bind to proteins, or of the metabolic or excretion rate of one or even two of the medications 
involved in the interaction concerned.10,11 Faced with considerable increases in the proportion 
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ABSTRACT
BACKGROUND: The scientific literature has shown that an association between polypharmacy and frailty 
exists. However, few studies have also considered drug interactions and the use of potentially inappropri-
ate medications.
OBJECTIVE: To evaluate the association between the use of drugs and frailty among community-dwelling 
older people.
DESIGN AND SETTING: Cross-sectional study carried out among 580 older people in Uberaba (MG). 
METHODS: Data were collected at these older people’s homes using instruments validated in Brazil. 
Descriptive, bivariate and binary logistic regression analyses were performed (P < 0.05).
RESULTS: Most of these individuals were classified as pre-frail (55.7%), while 13.1% were frail. It was found 
that 31.7% of them presented polypharmacy, 41.7% had drug interactions and 43.8% were using poten-
tially inappropriate medications. In the initial model, polypharmacy (odds ratio, OR = 1.91; confidence in-
terval, CI = 1.27-2.86) and use of potentially inappropriate medications (OR = 2.45; CI = 1.68-3.57) increased 
the chance that these older people would be pre-frail or frail. In the final adjusted model, use of potentially 
inappropriate drugs remained associated with the outcome (OR = 2.26; CI = 1.43-3.57). 
CONCLUSION: Use of potentially inappropriate medications was the independent variable that explained 
the occurrence of frailty in a representative sample of community-dwelling older adults.
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of drug prescriptions issued to older people and the consequent 
increased risk of adverse events among these individuals, there is 
concern regarding identification and prevention of undesirable 
combinations and use of PIMs. 
It is known that PIMs increase the chances of adverse outcomes 
among older adults and that these are exacerbated when frailty 
syndrome is present.9,13,14 Nevertheless, studies in the scientific lit-
erature on this topic have focused on demonstrating the associa-
tion between polypharmacy and frailty,15,16 but without including 
evaluations of DIs and PIMs. It is also worth mentioning that older 
people, including frail individuals, experience reduced efficacy of 
medications, in addition to higher risk of adverse effects.17 The pos-
sible explanations for this phenomenon include impaired physio-
logical systems that combat frailty, drug interactions, drug-disease 
interactions and reduced adherence to medication. Additionally, 
adverse reactions to medications go unnoticed and can lead to 
other prescriptions.17 
The existence of this gap in knowledge emphasizes the need 
for clarifications regarding the relationship of these variables with 
frailty syndrome among community-dwelling older people. Better 
knowledge of the implications arising from variables relating to 
use of drugs can improve preventive clinical approaches towards 
the embrittlement process among older people. This could lead to 
significant differences in quality of life during the aging process.
OBJECTIVE
The objective of this study was to evaluate the association 




This cross-sectional study consisted of a household survey 
conducted among older people living in the urban area of  the 
city of Uberaba, Minas Gerais, in the southeastern region of 
Brazil. This study followed the guidelines of the Checklist for 
Reporting Results of Internet E-Surveys and the guidelines 
for Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE).
Sample
The sample size calculation considered a prevalence of frailty 
of 12.8%,6 accuracy of 2.7% and a 95% confidence interval for 
a finite population of 36,703 older people. From this, the sam-
ple size was determined as 579 subjects. However, allowance 
was made for a sampling loss of 20% and therefore it was calcu-
lated that the maximum number of individuals to be approached 
would be 724 elderly people. To define the study population, a 
multistage cluster sampling process was used, considering cen-
sus tracts, with information on neighborhoods and streets pro-
vided by the Brazilian Institute for Geography and Statistics. 
Tracts were drawn in order to subsequently select older people 
living in these tracts.
Older adults aged 60 or older, who were living in the urban area 
of  the municipality and who were able to walk, were included in the 
study. It needs to be highlighted that, in Brazil, people aged 60 years 
or over are considered to be older adults, according to the current 
legislation.18 
Subjects were excluded from this study in the following situa-
tions: presentation of cognitive decline, as assessed using the Mini 
Mental State Examination (MMSE);19 failure to locate the individ-
ual after three visits; hospitalization and/or institutionalization; 
and inability to undergo the assessment of frailty. This assessment 
because impossible if the subject presented inability to walk, severe 
sequelae from stroke, localized loss of strength and aphasia, or a 
severe or unstable stage of Parkinson’s disease and associated severe 
impairment of motility, speech or cognition. 
In the end, a total of 768 older people were approached, tak-
ing into account both the inclusion criteria and the losses, which 
comprised 154 due to cognitive decline and 34 due to incomplete 
tests for frailty evaluation. Hence, 580 patients were assessed in 
the present study.
Data collection
The interviews took place in the older people’s homes, in the 
period from March to June 2016. They were conducted by 
trained interviewers with previous experience in collecting data. 
Five supervisors, who had previously been selected, checked the 
interviews to verify the filling out and consistency of the items, in 
order to ensure quality control.
Explanatory and adjustment variables
The explanatory and adjustment variables were collected using 
a structured questionnaire that sought the following informa-
tion: (1) socioeconomic: age (numerical variable) and/or age 
group in years (60 to 69, 70 to 79 and 80 or older); gender (male 
or female); marital status (with or without a partner); school-
ing, in years (no education, 1 to 4 years and 5 years or more); 
individual monthly income, in minimum wages (no income, ≤ 
1 minimum wage and > 1 minimum wage); and (2) number of 
self-reported morbidities (0, 1 to 4 and 5 or more), as described 
in a previous study.20 
Frailty syndrome (dependent variable)
Presence of frailty syndrome, which was taken to be the depen-
dent variable, was identified through the five items that were pro-
posed as components of the frailty phenotype by Fried et al.:1 
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1. Unintentional weight loss: assessed through the question: 
“In the last year, did you lose more than 4.5 kg without inten-
tion (that is, without dieting or exercise)?”. 
2. Self-report of exhaustion and/or fatigue: assessed through 
two questions from the Brazilian version of the Center for 
Epidemiological Studies (CES-D) depression scale, i.e. item 
7 (“Did you feel you had to make an effort to cope with your 
usual tasks?”) and item 20 (“Were you unable to carry on with 
your things?”). The elderly people with a score of 2 or 3 in either 
of these questions met the frailty criterion for this item.21 
3. Decreased muscle strength, as assessed from handgrip strength 
using a manual hydraulic dynamometer (Model SH5001, 
SAEHAN, São Paulo, Brazil) and adopting the cutoff points 
proposed by Fried et al.1 
4. Slow gait speed, obtained from the gait time (in seconds) that 
was needed to cover a distance of 4.6 meters, using the cutoff 
points proposed by Fried et al.1  
5. Low level of physical activity, as ascertained from the long 
version of the International Physical Activity Questionnaire 
(IPAQ), adapted for older people.22 The classification used for 
this component considered older people to be inactive if they 
had 0-149 minutes of physical activity per week.23 
The older people who were positive for three or more of these 
items were classified as frail and those who were positive for one 
or two items were classified as pre-frail. Those who were negative 
in all the tests were considered to be robust or non-frail.1 
Drug use (independent variables)
To assess the variables relating to drug use, the older subjects 
were first asked: “Could you show me the medications you are 
currently using?” Thus, they were asked about their medical pre-
scriptions and the packaging of the drugs that were being used 
at the time of data collection. The following were recorded: the 
pharmaceutical form of the medicinal products, the amounts 
consumed and the number of applications per day. Based on 
these data, situations of polypharmacy, DIs and PIMs were eval-
uated, as described below.
Polypharmacy was checked by counting the number of med-
ications used by each older individual. When these older people 
reported using five or more medications, they were deemed to 
present polypharmacy.8 
Occurrences of DIs were also assessed through the Micromedex 
Drug Reax System (Greenwood Village, Colorado, USA), using 
its online access platform,24 which contains evidence-based infor-
mation on drugs and diseases. This tool allowed identification of 
the DIs that occurred (drug-drug) and ranked them according 
to severity (severe, moderate or mild). It is worth noting that 
this tool is widely recognized worldwide for use by healthcare 
professionals, including pharmacists, to obtain unbiased data. 
The value of this tool has been sustained through systematic 
reviews on the subject.24
Use of PIMs was classified in accordance with the cri-
teria established in the Brazilian Consensus on Potentially 
Inappropriate Drugs for Older People.12 To analyze this vari-
able, the subjects were divided between: “Using PIMs”, when 
it was found that they were using at least one drug classified 
as inappropriate; and “Not using PIMs” when they did not use 
any of these drugs.
Data analysis
The data were entered into an electronic spreadsheet in the Excel 
software, in duplicate, in order to identify any possible inconsis-
tencies from data entry. Subsequently, the data were imported 
into the Statistical Package for the Social Sciences (SPSS) soft-
ware, version 22.0 (New Orchard Road, Armonk, New York, 
USA), to carry out the analyses.
A descriptive statistical analysis was conducted by distribut-
ing absolute and percentage frequencies. The bivariate analysis on 
the socioeconomic characteristics and variables relating to use of 
drugs according to frailty condition was done using the chi-square 
test. To assess associations among use of polypharmacy, PIMs 
and DIs in relation to the frailty syndrome, the logistic regres-
sion model was adopted. In this model, the outcome variable was 
recategorized so as to become dichotomous (frail/pre-frail versus 
non-frail). In the final adjusted model, the independent variables 
were included (polypharmacy, use of PIMs and DIs), along with 
other potential confounding variables such as gender, age, edu-
cation and number of self-reported morbidities. For all analyses, 
the tests were considered significant when P < 0.05.
Ethical considerations
This study was approved by the human-research ethics commit-
tee of the Federal University of Triângulo Mineiro (Universidade 
Federal do Triângulo Mineiro, UFTM), under protocol no. 
493,211, dated December 13, 2013. 
RESULTS
Out of the total number of participants (n = 768), 154 older peo-
ple were excluded because they presented cognitive decline and 
34 because of inability to perform the comprehensive evaluation 
of the components of the frailty phenotype. Thus, the final sam-
ple consisted of 580 older adults.
In comparing the older people who were excluded with those 
who participated in the study, it was found that for both groups, the 
majority were female (70.7% versus 68.1%; P = 0.418); were living 
without a partner (71.3% versus 52.4%; P = 0.353 ); had had one 
to four years of schooling (56.4 versus 52.6%; P = 0.352); had a 
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monthly income of less than or equal to two minimum salaries 
(88.2% versus 81.6%; P = 0.979); and had five or more self-reported 
morbidities (64.7% versus 62.4%; P = 0.493). Regarding the age 
groups, older people aged 70 to 79 years (30.9%) predominated 
among the excluded individuals; while older adults aged 60 to 
69 years (44.1%) predominated among those who participated in 
the study. However, there was no significant difference regarding 
age groups (P = 0.645).
Based on the final sample (n = 580), the frailty status among the 
subjects was as follows: 13.1% (n = 76) were frail; 55.7% (n = 323) 
were pre-frail; and 31.2% (n = 181) were non-frail. 
It was found that most of the participants were female (68.1%); 
were between 60 and 69 years old (44.1%); were living without a 
partner (52.4%); had had one to four years of schooling (52.6%); 
and had a monthly income of two minimum wages (46.0%), fol-
lowed by ≤ 1 minimum wage (44.7%). In analyzing the sociode-
mographic variables according to the frailty classification, a higher 
percentage of older people aged 70 to 79 years (P < 0.001) and with 
no education (P = 0.008) was observed in the frail and pre-frail 
groups, compared with the non-frail group. It was also observed 
A higher proportion of older people with five or more frail and 
pre-frail morbidities was also observed, in relation to the non-frail 
ones (P = 0.013) (Table 1). 
Presence of polypharmacy was found in 31.7% (n = 184) of the 
older people. It was found that 41.7% (n = 242) had at least one DI 
and 43.8% (n = 254) were using PIMs. Occurrence of these events 
was more common among the frail older people, among whom 
51.3% (n = 39) presented polypharmacy (P < 0.001), 60.5% (n = 46) 
had DIs (P = 0.001) and 53.9% (n = 41) had PIM use (P < 0.001), 
in comparison with the other groups (Figure 1).
In logistic regression analysis, it could be seen in the initial 
model that presence of polypharmacy (odds ratio, OR = 1.91; con-
fidence interval, CI = 1.27-2.86) and use of PIMs (OR = 2.45; CI = 
1.68-3.57) increased the odds of occurrence of frailty/pre-frailty 
among these community-dwelling older people. Evaluation of the 
final adjusted model showed that use of PIMs remained associated 
with increased chances of occurrence of frailty/pre-frailty (OR = 
2.33, CI = 1.47-3.70), regardless of gender, age group, number of 
self-reported morbidities, education or other variables relating 
to use of medications (polypharmacy and DIs). It is notewor-
thy that age was also an explanatory variable for occurrences of 
frailty (Table 2).
DISCUSSION
The data from this study highlight that frailty among older 
people is a serious public health problem, given that signifi-
cant prevalence (13.1%) of this event among elderly individu-
als living in their own homes was demonstrated. This finding 
was similar to what has been found in other studies conducted 
in Brazil and worldwide that also used Fried’s phenotype: 
12.8%,6 14.8%,25 10%26 and 14%.27 However, it differed from 
others that have identified higher prevalences (47%28 and 
65.25%29) through using the Tilburg Frailty Indicator (TFI) 
concept and instrument.
This divergence of results was expected, given that the preva-
lence of frailty may vary according to the diagnostic instrument, 
Table 1. Absolute and percentage frequency distributions of the sociodemographic and health variables of the elderly subjects, 












Male 30.4 (55) 34.4 (111) 25.0 (19) 31.9 (185)
0.252
Female 69.6 (126) 65.6 (212) 75.0 (57) 68.1 (395)
Age group (in years)
60 to 69 59.1 (107) 39.3 (127) 28.9 (22) 44.1 (256)
< 0.00170 to 79 35.4 (64) 42.4 (137) 38.2 (29) 39.7 (230)
80 or older 5.5 (10) 18.3 (59) 32.9 (25) 16.2 (94)
Marital status
Companion 48.1 (87) 52.6 (170) 47 (61.8) 304 (52.4)
0.130
No companion 51.9 (94) 47.4 (153) 29 (38.2) 276 (47.6)
Education 
(years of schooling)
No education 11.6 (21) 16.1 (52) 23.7 (18) 15.7 (91)
0.0081 to 4 47.5 (86) 55.7 (180) 51.3 (39) 52.6 (305)
5 or more 40.9 (74) 28.2 (91) 25.0 (19) 31.7 (184)
Monthly income 
No income 11.6 (21) 9.0 (29) 5.3 (4) 9.3 (54)
0.132≤ 1 minimum wage 39.8 (72) 44.6 (144) 56.6 (43) 44.7 (259)
> 2 minimum wages 48.6 (88) 46.4 (150) 38.2 (29) 46.0 (267)
Number of morbidities
0 4.4 (8) 1.3 (4) 0 (0) 2.1 (12)
0.0131 to 4 37.6 (68) 36.8 (119) 25.0 (19) 35.5 (206)
5 or more 58.0 (105) 61.9 (200) 75.0 (57) 62.4 (362)
*Chi-square test.
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methodological standardization, plurality of existing concepts and 
variability of sample composition.30 A systematic review by Collard 
et al. showed that there was marked variation in the prevalence 
of frailty among community-dwelling older people, from 4.0% to 
59.1%.31 These data emphasize the need for these differences to be 
considered not only by healthcare professionals in evaluating older 
Polypharmacy
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Figure 1. Occurrences (%) of polypharmacy, drug interaction and use of potentially inappropriate medication for elderly people, 
according to the frailty phenotype classification; Brazil, 2016.
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people within clinical practice but also by managers in formulat-
ing public health policies.31
Since drug prescription is a participant in the frailty process, 
its quality requires special attention from healthcare professionals. 
The aging process makes older people more susceptible to devel-
oping chronic conditions, which eventually leads to use of several 
medications concomitantly.9 This, together with the pharmacoki-
netic and pharmacodynamic changes that occur with advancing 
age, results in exacerbated adverse effects, especially when the 
frailty syndrome is present.9,32 
These results converge with findings that were highlighted 
by other researchers, through demonstration of the association 
between polypharmacy and frailty in the initial logistic regres-
sion model.15,16,33 According to the International Frailty Consensus, 
polypharmacy is a possible cause of increased pathogenesis of 
frailty. Hence, reduction of the use of drugs for older people is 
recommended, among other clinical guidelines.7 A longitudinal 
study on Japanese older people found that those who used six or 
more drugs were at higher risk of developing frailty, in relation 
to the others, over a six-year period.34 It is worth considering, 
however, that polypharmacy did not remain associated with an 
increased chance of frailty in the adjusted model of the pres-
ent study, and this was also seen in other studies.29,35 These data 
highlight the importance of including other variables associated 
with evaluation of the quality of drug use among older people 
within clinical practice.
The relationship between DI and frailty was also analyzed in 
the present study but no significant association was found, either 
in the initial logistic regression model or in the adjusted model. 
Pagno et al. found that 52.2% of the older people were exposed 
to DIs, which was a result similar to that of the present study. 
They also found that most older people with DIs were classified 
as frail (68.2%) and demonstrated that exposure of older people 
to DIs increased the chance of this outcome. However, they did 
not carry out multivariate analysis with adjustment for other vari-
ables.33 It is important to note that most of the researchers who 
have evaluated DIs among older people did not consider frailty 
to be a factor associated with this event, as seen in an integrative 
review of the literature conducted by Rodrigues and Oliveira.3 
Hence, there is a need for further clarification of this relationship 
through additional studies. 
In the current study, use of PIMs was the independent variable 
that explained the increased chances of occurrence of frailty, thus 
confirming other findings that have been described in the litera-
ture.33,36-39 The hypotheses that might contribute towards under-
standing this association include the following: 
a) Use of PIMs can worsen older people’s clinical state, thereby 
interfering with their quality of life and increasing the mag-
nitude of adverse health outcomes;12,33 and these occurrences 
are exacerbated when frailty syndrome is present.9,13,14 
b) Among the adverse outcomes relating to use of PIMs, a strong 
association with functional decline has been shown;36 this is 
significantly correlated with frailty syndrome, as shown by 
Fried et al.1 
c) PIMs can affect the components that are measured in the frailty 
phenotype, such as weakness, low gait speed or low levels of 
physical activity.1,36
The findings of the current study demonstrated that use of 
PIMs was highly prevalent among these community-dwelling 
Table 2. Logistic regression models to verify associations among polypharmacy, drug interaction and use of potentially inappropriate 
medications in relation to the elderly frailty phenotype, Brazil, 2016
Pre-frail/frail Pre-frail/frail
Initial model Adjusted final model
OR CI OR CI
Polypharmacy
No 1 1 1 1
Yes 1.91‡ 1.27-2.86‡ 1.23 0.69-2.19
DI
No 1 1 1 1
Yes 1.42 0.99-2,04 0.77 0.46-1.28
PIM
No 1 1 1 1
Yes 2.45‡ 1.68-3.57‡ 2.33‡ 1.47-3.70‡
Gender
Female - - 1 1
Male - - 0.79 0.52-1.21
Age - - - 1.08‡ 1.05-1.11‡
Education
No education
1 to 4 years 0.79 0.58-1.04
Number of diseases - - - 1.04 0.98-1.11
Reference category = non-frail; ‡P < 0.001; 1 = reference category.
OR = odds ratio; CI = confidence interval; DI = drug interactions.
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older people and that its presence was associated with occur-
rences of frailty. These findings are concordant with the clinical 
guidance for management of frailty, in which reduction or depre-
scription of potentially inappropriate medication for older adults 
is strongly recommended.40 Curtin et al. used the STOPPFrail 
criteria and demonstrated that this is a tool that removes an 
important barrier against deprescription of medications through 
explicitly highlighting the circumstances in which commonly 
used medications can be safely deprescribed among older peo-
ple with advanced frailty.41
Professionals working within primary healthcare are in closer 
contact with community-dwelling older people and, therefore, 
should incorporate evaluation of use of PIMs in their overall 
routine for geriatric assessment. In this regard, the International 
Frailty Consensus recommends use of the Beers and STOPPFrail 
criteria within clinical practice. When use of PIMs is identified, 
the older individuals presenting this usage should be referred 
for medical evaluation, in order to optimize their medication 
treatment and, therefore, prevent frailty syndrome. Lavan et al. 
found that almost 65% of their patients awaiting long-term care 
were eligible for application of the STOPPFrail criteria, such 
that over 90% of these had been prescribed at least one PIM. 
They concluded that the transition to nursing-home care rep-
resented an opportunity to review the therapeutic appropri-
ateness and goals of the medications that had been prescribed 
for these individuals.42
Although use of PIMs was the only explanatory independent 
variable for frailty syndrome in the present study, the importance 
of evaluating polypharmacy and DIs cannot be overlooked. It is 
known that both the presence of PIM and the presence of poly-
pharmacy tend to make frail older people more prone to negative 
events, such as increased risk of adverse effects, mostly coming 
from DIs. These relationships can be explained in terms of the 
changes and features present in frail older people that make them 
more vulnerable to manifestations of DIs and health problems 
arising from them.33,43,44
In addition, several studies have shown that use of multiple 
medications is associated with use of PIMs.38,45-51 Other authors 
have shown, however, that the risk of using PIMs is greater among 
individuals with higher numbers of morbidities and who, thus, 
have to use more drugs.48,52,53 Pagno et al. also identified that the 
prevalence of frailty was higher in the presence of PIMs that 
were involved in DIs.33 Moreover, Lorenzo-López et al. con-
firmed the dynamics of frailty and the bidirectional nature of 
frailty transitions, thus indicating the need for prevention and 
treatment of these conditions in later life, in order to minimize 
the burden of frailty.54
The findings from the present study need to be considered 
cautiously due to its cross-sectional nature, which did not allow 
cause-and-effect relationships to be established among the vari-
ables. Moreover, it needs to be borne in mind that a self-report 
questionnaire was used to investigate morbidities, which meant 
that some of the information found may have been underestimated 
or overestimated. Therefore, use of cohort studies among commu-
nity-dwelling older people is suggested, in order to assess the effect 
of interactions among the variables of DI, PIM and polypharmacy, 
regarding occurrences of frailty syndrome. 
CONCLUSION
It was found that use of inappropriate medications was the inde-
pendent variable that explained the occurrences of frailty in this 
representative sample of community-dwelling older people in a 
Brazilian municipality. However, this study showed that there is 
a need for research with a longitudinal design, in order to assess 
the causality of these conditions in relation to frailty. 
Nevertheless, the data obtained in this study constitute an 
advance in this field of knowledge, since they indicate the need 
for advanced practices, with application of explicit methods for 
evaluation of drug use within primary healthcare, with a view to 
improving the quality of life of older people living in their own 
homes. Thus, in clinical practice, accurate analysis with the use of 
validated tools and technologies for monitoring and recognition 
of polypharmacy, potential drug interactions and inappropriate 
use of drugs can optimize the adequacy of prescription and hence 
minimize problems relating to these medications, thereby dimin-
ishing the onset of frailty.
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